AstraZeneca China deal channels two key hopes
This article was originally published in Scrip
Executive Summary
In signing a deal with Shenzhen University in China, AstraZeneca has covered two important bases in its hopes for future growth. The UK-based firm's Shanghai Innovation Center will work with the university's newly established Nephrology and Urology Center on preclinical research into chronic kidney disease (CKD), with a particular focus on the damage to kidneys caused by diabetes.